Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Boehringer Ingelheim
Modality
antibody_drug_conjugate
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06324357CT.gov Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Esophageal Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Trastuzumab Emtansine (this asset) | Boehringer Ingelheim | P1/2 | CC · 43 |
| Cetuximab | BeOne Medicines | P2 | B |
| Capecitabine | I-Mab Biopharma US Limited | P3 | B |
| Oxaliplatin | I-Mab Biopharma US Limited | P3 | B |
| Tislelizumab | BeOne Medicines | P3 | B |
| Fluorouracilum | I-Mab Biopharma US Limited | P3 | B |
| Durvalumab | University of California, Irvine | P2 | B |
| Cis-Diamminedichloroplatinum Ii | Taiho Oncology, Inc. | P3 | B |
| Trastuzumab | Boehringer Ingelheim | P3 | B |
+42 more in the Esophageal Adenocarcinoma cohort
Other indications for Trastuzumab Emtansine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Cancer | — | P3 | BB · 66 |
| Breast Carcinoma | — | P3 | BB · 66 |
| HER2 Positive Breast Carcinoma | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Trastuzumab Emtansine in Esophageal Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/trastuzumab-emtansine-esophageal-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →